ArticleInternational journal of clinical oncology2020
Risk factors for lower limb lymphedema in gynecologic cancer patients after initial treatment.
Article in International journal of clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Risk factors for lower limb lymphedema after gynecological cancer treatment: a systematic review.Frontiers in oncology · 2025Pooled it
- Positive Impact of a New Compressive Garment in Patients with Genital Lymphedema: OLYMPY Study.Lymphatic research and biology · 2024Trial
- Trial
- A prospective assessment of simple lymphatic drainage to prevent lower limb lymphedema in gynecological malignancies.Scientific reports · 2025Article
- A 5-year prospective assessment of risk factors for lower limb lymphedema after gynecologic cancer surgery.Scientific reports · 2025Article
- Etiology and treatment of cancer-related secondary lymphedema.Clinical & experimental metastasis · 2024Review
- Primary surgical prevention of lymphedema.Journal of the Chinese Medical Association : JCMA · 2024Review
- Lymphedema self-assessment among endometrial cancer survivors.Cancer causes & control : CCC · 2024Article
- Supermicrosurgical lymphovenous anastomosis.Journal of the Chinese Medical Association : JCMA · 2024Review
- Retrospective study on the trajectories of lower limb volume after outpatient-based complex decongestive therapy in post-operative gynecological cancer patients with lymphedema.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Risk factors for lower extremity lymphedema after surgery in cervical and endometrial cancer.Journal of gynecologic oncology · 2023Article
- Review
- A new severity classification of lower limb secondary lymphedema based on lymphatic pathway defects in an indocyanine green fluorescent lymphography study.Scientific reports · 2022Article
- Article
- Cancer-related lymphedema: clinical pearls for providers.Current oncology (Toronto, Ont.) · 2020Review
- Comprehensive Decongestive Therapy as a Treatment for Secondary Lymphedema of the Lower Extremity and Quality of Life of Women After Gynecological Cancer Surgery.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMost studies on lower limb lymphedema have been conducted in gynecologic cancer patients who underwent surgery for gynecologic malignancy. This study aimed to evaluate the risk factors for lower limb lymphedema development in gynecologic cancer patients who underwent initial treatment.
methodsA retrospective cohort design was used to follow 903 gynecologic cancer patients who underwent treatment at Kurume University Hospital between January 1, 2013 and December 31, 2015. Data analyses were performed in 356 patients, and the patients were followed up until December 31, 2017. The model comprised two components to facilitate statistical model construction. Specifically, a discrete survival time model was constructed, and a complementary log-log link model was fitted to estimate the hazard ratio. Associations between risk factors were estimated using generalized structural models.
resultsThe median follow-up period was 1083 (range 3-1819) days, and 54 patients (15.2%) developed lower limb lymphedema, with a median onset period of 240 (range 3-1415) days. Furthermore, 38.9% of these 54 patients developed lower limb lymphedema within 6 months and 85.2% within 2 years. International Federation of Gynecology and Obstetrics stage, radiotherapy, and number of lymph node dissections (≥ 28) were significant risk factors.
conclusionSimultaneous examination of the relationship between lower limb lymphedema and risk factors, and analysis among the risk factors using generalized structural models, enabled us to construct a clinical model of lower limb lymphedema for use in clinical settings to alleviate this condition and improve quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.